Showing 1 - 8 results of 8 for search 'Walter C. Olson', query time: 0.05s
Refine Results
-
1
-
2
-
3
Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates by Craig L Slingluff, Walter C Olson, Christine A Tran, Arabinda Mandal, Jagathpala Shetty, Mriganka Mandal, Bhupal Ban, Eusebio S Pires, Sara J Adair, Todd W Bauer, John C Herr
Published 2024-03-01
Article -
4
Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist by Craig L Slingluff, Gina R Petroni, Walter C Olson, Kimberly A Chianese-bullock, Donna Deacon, Mark Smolkin, William W Grosh, Max O Meneveau, Kevin T Lynch, Elise P Salerno, Elizabeth Woodson, James W Patterson
Published 2021-05-01
Article -
5
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64) by Ileana S Mauldin, Craig L Slingluff, Gina R Petroni, Walter C Olson, Kimberly A Chianese-bullock, Kelly T Smith, Nikole Varhegyi, William W Grosh, Kathleen Haden, Lynn T Dengel, Elizabeth M Gaughan, Varinder Kaur, Rick Daniel Vavolizza
Published 2022-09-01
Article -
6
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma by Patrick Hwu, Jason Roszik, Gina R Petroni, Walter C Olson, Kimberly A Chianese-bullock, Kelly T Smith, Nikole Varhegyi, Elizabeth Gaughan, Mark Smolkin, Sacha Gnjatic, Nolan A Wages, Emily H Hall, Kathleen Haden, Sapna P Patel
Published 2021-08-01
Article -
7
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer by Patrick M. Dillon, Gina R. Petroni, Mark E. Smolkin, David R. Brenin, Kimberly A. Chianese-Bullock, Kelly T. Smith, Walter C. Olson, Ibrahim S. Fanous, Carmel J. Nail, Christiana M. Brenin, Emily H. Hall, Craig L. Slingluff
Published 2017-11-01
Article -
8
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma by Craig L. Slingluff, Hassane M. Zarour, Hussein Abdul-Hassan Tawbi, John M. Kirkwood, Michael A. Postow, Philip Friedlander, Craig E. Devoe, Elizabeth M. Gaughan, Ileana S. Mauldin, Walter C. Olson, Kelly T. Smith, Mary J. Macri, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok
Published 2021-01-01
Article